Last reviewed 2026-04-23 · How we verify

PMF104

PMF104 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels.

PMF104 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels. Used for Inflammatory bowel disease (IBD) or related gastrointestinal inflammatory conditions.

At a glance

Mechanism of action

PDE4 inhibition leads to accumulation of cyclic adenosine monophosphate (cAMP) in immune and inflammatory cells, suppressing the release of pro-inflammatory cytokines and chemokines. This mechanism is intended to reduce excessive inflammatory responses in conditions characterized by dysregulated immune activation.

Approved indications

• Inflammatory bowel disease (IBD) or related gastrointestinal inflammatory conditions

Common side effects

• Nausea
• Diarrhea
• Headache
• Vomiting

Key clinical trials

• A Trial to Evaluate the Efficacy and Safety of PMF104 Compared to a Conventional PEG-electrolyte Solution in Children (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.